Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a
BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid …

In 2007, we conducted a prospective randomized study to compare an aggressive dose
escalation (group B, n= 123) with the standard dose escalation proposed by European …

Imatinib has revolutionized treatment strategies for chronic myeloid leukemia patients: long-
term overall survival was reported to be up to 80% at 8years of follow-up in respondent …

When imatinib, the first tyrosine kinase inhibitor (TKI) developed for use in chronic
myelogenous leukemia (CML), was approved in 2001, the treatment of this disease was …

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with
imatinib (IM) at 400 mg/day (n= 400) could be optimized by doubling the dose (n= 420) …

Purpose: Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL
fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia …

Abstract Background: Imatinib mesylate (IM) 400 mg/d is the standard of care for newly
diagnosed patients (pts) with CML-CP. Dose escalation to 600 or 800 mg IM has been …

Despite considerable skepticism about any possible clinical value of tyrosine kinase
inhibitors (TKIs) in the early 1990s, Druker et al, 1 in conjunction with scientists at Ciba …

Objective: To discuss new therapeutic options available in the treatment of chronic
myelogenous leukemia (CML) in patients who (ailed or were intolerant to imatinib therapy …

Imatinib therapy is an important contribution to the management of patients with chronic
myelogenous leukemia (CML). Despite high rates of hematologic and cytogenetic …